切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2019, Vol. 13 ›› Issue (06) : 467 -471. doi: 10.3877/cma.j.issn.1674-1358.2019.06.002

所属专题: 文献

综述

乳酸杆菌与肝病研究进展
全敏1, 邢卉春1,()   
  1. 1. 100015 北京,首都医科大学附属北京地坛医院肝病三科
  • 收稿日期:2019-01-11 出版日期:2019-12-15
  • 通信作者: 邢卉春
  • 基金资助:
    北京市重点实验室开放研究课题(No. DTKF201704); 北京市医院管理局消化内科学科协同发展中心项目(No. XXT26); 北京市医院管理局扬帆计划(No. XMLX201837); "十三五"艾滋病和病毒性肝炎等重大传染病防治(No. 2018ZX10302206-003-006); 吴阶平医学基金会(No. LDWJPMF-103-17001)

Progress on Lactobacillus and liver diseases

Min Quan1, Huichun Xing1,()   

  1. 1. Department of Hepatology Division 3rd, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
  • Received:2019-01-11 Published:2019-12-15
  • Corresponding author: Huichun Xing
  • About author:
    Corresponding author: Xing Huichun, Email:
引用本文:

全敏, 邢卉春. 乳酸杆菌与肝病研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2019, 13(06): 467-471.

Min Quan, Huichun Xing. Progress on Lactobacillus and liver diseases[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2019, 13(06): 467-471.

近年来肠道微生态与多种肝病的发生、发展受到越来越多的关注。益生菌因具有改善肠道屏障、激活免疫功能等多种有利于人体的功能而日益受到重视。乳酸杆菌作为主要的益生菌之一,与多种肝脏疾病的发生、发展和预后相关,尤其在酒精性脂肪肝及非酒精性脂肪肝治疗中作用的研究日益增多。不同乳酸杆菌与不同肝病的关系亦不尽相同,为临床应用乳酸杆菌调节肠道菌群及治疗肝病提供参考,本文就乳酸杆菌与肝病相关性及在肝病治疗中的应用作一综述。

In recent years, more and more attention has been paid to the relationship between intestinal microecology and the occurrence and development of various liver diseases. Probiotics are getting more and more attention due to their beneficial functions such as improving intestinal barrier and activating immune function. Lactobacillus, as one of the main probiotics, is associated with the occurrence, development and prognosis of various liver diseases, especially in the treatment of alcoholic fatty liver disease and non-alcoholic fatty liver disease. In order to provide reference for the clinical application of Lactobacillus in the regulation of intestinal flora in the treatment of liver diseases, this paper reviews the correlation between Lactobacillus and liver diseases and its application in the treatment of liver diseases.

[1]
Lachar J, Bajaj JS. Changes in the Microbiome in cirrhosis and relationship to complications: Hepatic encephalopathy, spontaneous bacterial peritonitis, and sepsis[J]. Semin Liver Dis,2016,36(4):327-330.
[2]
Marteau P, Shanahan F. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects[J]. Best Pract Res Clin Gastroenterol,2003,17(5):725-740.
[3]
Ou CC, Lin SL, Tsai JJ, et al. Heat-killed lactic acid bacteria enhance immunomodulatory potential by skewing the immune response toward Th1 polarization[J]. J Food Sci,2011,76(5):M260-267.
[4]
Conway PL, Gorbach SL, Goldin BR. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells[J]. J Dairy Sci,1987,70(1):1-12.
[5]
Zhang M, Wang C, Wang C, et al. Enhanced AMPK phosphorylation contributes to the beneficial effects of Lactobacillus rhamnosus GG supernatant on chronic-alcohol-induced fatty liver disease[J]. J Nutr Biochem,2015,26(4):337-344.
[6]
Chen RC, Xu LM, Du SJ, et al. Lactobacillus rhamnosus GG supernatant promotes intestinal barrier function, balances Treg and TH17 cells and ameliorates hepatic injury in a mouse model of chronic-binge alcohol feeding[J]. Toxicol Lett,2016,241:103-110.
[7]
Wang Y, Liu Y, Kirpich I, et al. Lactobacillus rhamnosus GG reduces hepatic TNFα production and inflammation in chronic alcohol-induced liver injury[J]. J Nutr Biochem,2013,24(9):1609-1615.
[8]
Wang Y, Liu Y, Sidhu A, et al. Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury[J]. Am J Physiol Gastrointest Liver Physiol,2012,303(1):G32-41.
[9]
Kim B, Park KY, Ji Y, et al. Protective effects of Lactobacillus rhamnosus GG against dyslipidemia in high-fat diet-induced obese mice[J]. Biochem Biophys Res Commun,2016,473(2):530-536.
[10]
Hammes TO, Leke R, TDC E, et al. Lactobacillus rhamnosus GG reduces hepatic fibrosis in a model of chronic liver disease in rats[J]. Nutr Hosp,2017,34(3):702-709.
[11]
Bajaj JS, Heuman DM, Hylemon PB, et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis[J]. Aliment Pharmacol Ther,2014,39(10):1113-1125.
[12]
Messaoudi S, Manai M, Kergourlay G, et al. Lactobacillus salivarius: bacteriocin and probiotic activity[J]. Food Microbiol,2013,36(2):296- 304.
[13]
Guo J, Brosnan B, Furey A, et al. Antifungal activity of Lactobacillus against microsporum canis, microsporum gypseum and epidermophyton floccosum[J]. Bioeng Bugs,2012,3(2):104-113.
[14]
Steinberg RS, Silva LC, Souza TC, et al. Safety and protective effectiveness of two strains of Lactobacillus with probiotic features in an experimental model of salmonellosis[J]. Int J Environ Res Public Health,2014,11(9):8755-8776.
[15]
Drago L, De Vecchi E, Gabrieli A, et al. Immunomodulatory effects of Lactobacillus salivarius LS01 and Bifidobacterium breve BR03, alone and in combination, on peripheral blood mononuclear cells of allergic asthmatics[J]. Allergy Asthma Immunol Res,2015,7(4):409-413.
[16]
Lv LX, Hu XJ, Qian GR, et al. Administration of Lactobacillus salivarius LI01 or Pediococcus pentosaceus LI05 improves acute liver injury induced by D-galactosamine in rats[J]. Appl Microbiol Biotechnol,2014,98(12):5619-5632.
[17]
Lv LX, Yan R, Shi HY, et al. Integrated transcriptomic and proteomic analysis of the bile stress response in probiotic Lactobacillus salivarius LI01[J]. J Proteomics,2017,150:216-229.
[18]
Shi D, Lv L, Fang D, et al. Administration of Lactobacillus salivarius LI01 or Pediococcus pentosaceus LI05 prevents CCl4-induced liver cirrhosis by protecting the intestinal barrier in rats[J]. Sci Rep,2017,7(1):6927-6940.
[19]
Chuang CH, Tsai CC, Lin ES, et al. Heat-killed Lactobacillus salivarius and Lactobacillus johnsonii reduce liver injury induced by alcohol in vitro and in vivo[J]. Molecules,2016,21(11):1456-1467.
[20]
Nan B, Liu YL, You Y, et al. Protective effects of enhanced minor ginsenosides in Lactobacillus fermentum KP-3-fermented ginseng in mice fed a high fat diet[J]. Food Funct,2018,9(11):6020-6028.
[21]
Yadav R, Khan SH, Mada SB, et al. Consumption of probiotic Lactobacillus fermentum MTCC: 5898-fermented milk attenuates dyslipidemia, oxidative stress, and inflammation in male rats fed on cholesterol-enriched diet[J]. Probiotics Antimicrob Proteins,2018,
[22]
Rivero-Gutiérrez B, Gámez-Belmonte R, Suárez MD, et al. A synbiotic composed of Lactobacillus fermentum CECT5716 and FOS prevents the development of fatty acid liver and glycemic alterations in rats fed a high fructose diet associated with changes in the microbiota[J]. Mol Nutr Food Res,2017,61(8):201600622.
[23]
Jin P, Chen Y, Lv L, et al. Lactobacillus fermentum ZYL0401 attenuates lipopolysaccharide-induced hepatic TNF-α expression and liver injury via an IL-10- and PGE2-EP4-dependent mechanism[J]. PLoS One,2015,10(5):e0126520.
[24]
Kim BK, Lee IO, Tan PL, et al. Protective effect of Lactobacillus fermentum LA12 in an alcohol-induced rat model of alcoholic steatohepatitis[J]. Korean J Food Sci Anim Resour,2017,37(6):931-939.
[25]
Stadlbauer V, Mookerjee RP, Hodges S, et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis[J]. J Hepatol,2008,48(6):945-951.
[26]
Ren T, Huang C, Cheng M. Dietary blueberry and bifidobacteria attenuate nonalcoholic fatty liver disease in rats by affecting SIRT1-mediated signaling pathway[J]. Oxid Med Cell Longev,2014,2014:469059.
[27]
Wagnerberger S, Spruss A, Kanuri G, et al. Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model[J]. J Nutr Biochem,2013,24(3):531-538.
[28]
Zhao D, Wu T, Yi D, et al. Dietary supplementation with Lactobacillus casei alleviates Lipopolysaccharide-induced liver injury in a porcine model[J]. Int J Mol Sci,2017,18(12):2535-2547.
[29]
Zhang H, Wang Y, Sun J, et al. Safety evaluation of Lactobacillus paracasei subsp. paracasei LC-01, a probiotic bacterium[J]. J Microbiol,2013,51(5):633-638.
[30]
Ye H, Li Q, Zhang Z, et al. Effect of a novel potential probiotic Lactobacillus paracasei Jlus66 isolated from fermented milk on nonalcoholic fatty liver in rats[J]. Food Funct,2017,8(12):4539-4546.
[31]
Park SS, Lee YJ, Song S, et al. Lactobacillus acidophilus NS1 attenuates diet-induced obesity and fatty liver[J]. J Endocrinol,2018,237(2):87-100.
[32]
Li C, Nie SP, Zhu KX, et al. Lactobacillus plantarum NCU116 improves liver function, oxidative stress and lipid metabolism in rats with high fat diet induced non-alcoholic fatty liver disease[J]. Food Funct,2014,5(12):3216-3223.
[33]
Miyoshi M, Ogawa A, Higurashi S, et al. Anti-obesity effect of Lactobacillus gasseri SBT2055 accompanied by inhibition of pro-inflammatory gene expression in the visceral adipose tissue in diet-induced obese mice[J]. Eur J Nutr,2014,53(2):599-606.
[1] 郝玥萦, 毛盈譞, 张羽, 汪佳旭, 韩林霖, 匡雯雯, 孟瑶, 杨秀华. 超声引导衰减参数成像评估肝脂肪变性及其对心血管疾病风险的预测价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 770-777.
[2] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[3] 戴睿, 张亮, 陈浏阳, 张永博, 吴丕根, 孙华, 杨盛, 孟博. 肠道菌群与椎间盘退行性变相关性的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 546-549.
[4] 李嘉兴, 孙乙文, 李文星. NLRP3炎性小体在急性胰腺炎中作用的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(04): 300-304.
[5] 李玲, 刘亚, 李培玲, 张秀敏, 李萍. 直肠癌患者术后肠道菌群的变化与抑郁症相关性研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 607-610.
[6] 王雪玲, 曹欢, 顾劲扬. 肠道菌群在器官缺血再灌注损伤中的作用及机制研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(04): 247-250.
[7] 王淑贤, 张良灏, 王利君, 张慧, 郭源, 许传屾, 李志强, 蔡金贞, 解曼, 饶伟. 成人肝移植围手术期严重心血管事件危险因素分析及预测模型研究[J/OL]. 中华移植杂志(电子版), 2024, 18(04): 222-229.
[8] 方道成, 唐春华, 胡媛媛. 肠道菌群对草酸钙肾结石形成的影响[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 509-513.
[9] 蔡艺丹, 方坚, 张志强, 陈莉, 张世安, 夏磊, 阮梅, 李东良. 经颈静脉肝内门体分流术对肝硬化门脉高压患者肠道菌群及肝功能的影响[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 285-293.
[10] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[11] 宋燕秋, 戚桂艳, 杨双双, 周萍. 重症急性胰腺炎肠道菌群特征及早期肠内营养联合微生态制剂治疗的临床价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 442-447.
[12] 邱岭, 朱旭丽, 浦坚, 邢苗苗, 吴佳玲. 糖尿病肾病患者肠道菌群生态特点与胃肠道功能障碍的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 453-458.
[13] 赵小民, 杨军, 田巍巍. 枳术颗粒联合利那洛肽治疗便秘型肠易激综合征的临床研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 465-469.
[14] 陈利, 杨长青, 朱风尚. 重视炎症性肠病和代谢相关脂肪性肝病间的串话机制研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 385-389.
[15] 李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?